

## Special Issue

# Cardiovascular Disease: From Genetics to Therapeutics

### Message from the Guest Editor

Cardiovascular disease remains the leading cause of death worldwide, and there is a great unmet need for novel classes of therapeutics. The challenge for the field, then, is to find ways to accelerate variant-to-function discovery for cardiovascular disease. This will require the development of better computational models to predict variant functions and higher throughput approaches to link variants to molecular and cellular phenotypes, together with an intensified effort to discover disease mechanisms for individual causal genes and pathways and to develop new therapeutics to target them. This Special Issue cordially invites novel studies and review articles that address all aspects of genetics-to-therapeutics discovery for cardiovascular disease, including new genetic analyses/meta-analyses, predictive modeling, high-throughput variant-to-function approaches, single cell studies that identify pathogenic cell types or transcriptomic signatures, dissection of variant-to-disease mechanisms at individual loci, and efforts to develop new therapeutics targeting known or novel causal genes and pathways.

---

### Guest Editor

Dr. Gavin Schnitzler

1. The Broad Institute of Harvard & MIT, Cambridge, MA, USA
2. Brigham and Women's Hospital, Boston, MA, USA

---

### Deadline for manuscript submissions

closed (25 November 2024)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/si/206856](https://mdpi.com/si/206856)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Experimental Cancer Therapeutics, The University of Alabama at  
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-  
2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))